The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790M
Journal
Oncotarget
Journal Volume
7
Journal Issue
30
Pages
48059-48069
Date Issued
2016
Author(s)
Abstract
Different growth kinetics occurring between the sensitive and T790M-containing cells may result in the repopulation of tumor cells over time. Little information has yet been uncovered on whether rebiopsy timing influences the T790M detection rate. We enrolled a total of 98 epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients, who had a history of acquired resistance to EGFR-tyrosine kinase inhibitor (TKI) and available rebiopsy tumor specimens for reassessment of EGFR mutations. Rebiopsy was performed at the time of first EGFR-TKI progression in 54 patients (55.1%); for the other 44 patients (44.9%), rebiopsy was done with an interval from first EGFR-TKI progression (median 470.5 days, range 46-1742 days). Our results indicated that rebiopsy timing did not influence the detection rate of T790M and that the mutation could be identified in patients with a long EGFR-TKIfree interval. For patients without suitable lesions for rebiopsy at the time of EGFRTKI progression, an attempt to rebiopsy should be considered during the subsequent treatment courses.
SDGs
Other Subjects
afatinib; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; methionine; osimertinib; threonine; EGFR protein, human; epidermal growth factor receptor; protein kinase inhibitor; adult; amino acid substitution; Article; cancer patient; cancer resistance; controlled study; cytopathology; female; histopathology; human; human tissue; lung adenocarcinoma; lung biopsy; lung rebiopsy; major clinical study; male; mutational analysis; progression free survival; survival time; time to treatment; treatment response; adenocarcinoma; aged; antagonists and inhibitors; biopsy; disease exacerbation; drug resistance; enzymology; genetics; lung tumor; middle aged; mutation; pathology; very elderly; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Receptor, Epidermal Growth Factor
Type
journal article